FDA levels clinical hold on Magenta's second lead drug, asking for an additional bioassay before it gets to humans
Earlier this summer, Magenta Therapeutics was forced to say goodbye to its head of R&D at a pivotal time as the biotech read out data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
